Researchers from the University of Birmingham led this study, published in the journal eBioMedicine, which confirmed that patients suffering from major depressive disorder, including treatment-resistant depression, experienced significant and rapid improvements in their symptoms after short gas treatment sessions, according to Medscape. This analysis is the largest global consolidation of clinical trial data in this field, paving the way for a new generation of rapid treatments, unlike traditional medications that take weeks to show effectiveness.
Nitrous oxide is traditionally used as a pain reliever in medical procedures, such as dentistry and short operations, providing a feeling of relaxation without full loss of consciousness. The study explained that it represents an effective treatment option for adults suffering from severe or treatment-resistant depression, a condition where the patient does not respond to two separate antidepressant treatment attempts. This type affects about 48% of depression patients in the UK, who suffer from a lack of tangible response, making the search for rapid alternatives crucial.
Researchers conducted a systematic analysis of seven clinical trials and four research protocol papers from international teams, focusing on its use in treating major, resistant, and bipolar depression. The evaluation focused on levels of symptom improvement, dose concentration, continuity of effect, as well as physical and psychological safety. Repeated doses over weeks achieved more sustainable improvement, suggesting that multiple treatments are the optimal strategy for maintaining benefit.
The study explained the gas’s mechanism by targeting glutamate receptors, similar to the rapidly effective drug ketamine, which explains the quick improvement. Researchers confirmed that this similarity makes nitrous oxide a promising option in the category of rapid treatments, supported by its long medical history in pain relief.
The study stated, “The study gathers the best available evidence to assess the effectiveness of nitrous oxide, providing patients suffering from major depression a new glimmer of hope in a fast-acting treatment alternative, and serves as a basis for more extensive future trials to build precise protocols around doses and their repetition.” Despite the strong evidence for short-term mood improvement, the study pointed out the limited number of trials, causing differences in symptom measurement and timing of assessments.
Regarding safety, some patients recorded transient symptoms like nausea and dizziness, which quickly disappeared without intervention, with increased likelihood at a 50% concentration. No short-term security concerns were recorded in the trials, but future studies are needed to assess long-term safety.
Steven Marwaha, Professor of Psychiatry at the University of Birmingham and the lead author, praised: “Patients who fail to respond to traditional treatments often lose hope for recovery, and this group urgently needs new effective options.” He confirmed: “The study’s results highlight the urgent need to develop supportive treatments that can be integrated with current treatment pathways to enhance the chances of controlling depression symptoms.”
The team is currently working on the first clinical trial in the UK’s National Health Service to assess the safety and effectiveness of the gas in a real-world care environment, with results expected to help integrate it within and expand options for patients not benefiting from traditional methods. The study concluded by affirming that nitrous oxide, when used clinically under specialized medical supervision, could change the course of depression treatment, opening the way for a network of advanced trials that may make it a fixed part of treatment protocols in the coming years, especially for those who failed with traditional treatments.
